Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10‐year (2006–2015) retrospective hospitalization summary report‐based study

Abstract

BackgroundThis study was conducted to describe present and changing trends in surgical modalities and neoadjuvant chemotherapy (NACT) in female breast cancer patients in China from 2006 to 2015.MethodsData of 44 299 female breast cancer patients from 15 tertiary hospitals in Beijing were extracted from hospitalization summary reports. Surgeries were categorized into five modalities: breast‐conserving surgery (BCS), simple mastectomy (SM), modified radical mastectomy (MRM), radical mastectomy (RM), and extensive radical mastectomy (ERM).ResultsIn total, 38 471 (86.84%) breast cancer patients underwent surgery: 22.64% BCS, 8.22% SM, 63.97% MRM, 4.24% RM, and 0.93% ERM. Older patients (> 60) underwent surgery more frequently than younger patients (< 60). The proportion of patients who underwent BCS was highest in the age ≥ 80 (39.24%) and < 40 (28.69%) subgroups and in patients with papillary carcinoma (35.48%), and lowest in the age 60‐ subgroup (18.17%) and in patients with Paget's disease (19.05%). SM was most frequently performed in patients with Paget's disease (29.00%), and MRM for ductal (64.99%), and lobular (63.78%) carcinomas. During the study period, the proportion of patients who underwent MRM dropped by 29.04%, SM and BCS increased from 15.78% and 30.83%, respectively, and NACT increased in all subgroups, particularly in patients with lymph node involvement (26.72%).ConclusionsSurgical modalities varied significantly by age and histologic group. The use of BCS and SM increased dramatically, while MRM declined significantly. The proportion of patients treated with NACT has increased significantly, especially in patients with lymph node involvement.

Time trends of neoadjuvant chemotherapy for early breast cancer

“…There is only sparse comparable data on the use of neoadjuvant chemotherapy in recent years. Some reports showed rising rates of NACT of 39.7% in 2014 in China 35 and 35.2% for 2009 to 2011 in South Africa 36 . The use of NACT is also rising in the US but remains at a comparative low level with 23.5% in 2012 37 or 24.0% in 2011 38 …”

Development of a prediction model based on LASSO regression to evaluate the risk of non-sentinel lymph node metastasis in Chinese breast cancer patients with 1-2 positive sentinel lymph nodes

“…However, in most developing countries, such as China, the BCR is only approximately 20%, compared to 50%-80% in Western countries [6,16,17]. Even in some leading centres in China, the BCR is only 30% [18]. Because of the low BCR in developing countries and the absence of evidence for ALND omission in Eastern populations, most clinicians in developing countries such as China still hold a conservative view and recommend ALND for patients with positive SLNs [16].…”

The Characteristics Comparison of Breast Cancer Patients in Southern China and America: A Multicentre Study in China Versus SEER Database

“…At present, the main treatments of BC were surgery, radiotherapy, chemotherapy, targeted therapy and hormone therapy [44,45] . Among them, surgery can signi cantly reduce the mortality rate, which is the most critical step in the treatment of breast cancer, there are ve common surgical methods: Breast conserving surgery (BCS), simple mastectomy (SM), modi ed radical mastectomy (MRM), radical mastectomy (RM) and extensive radical mastectomy (ERM) [46] . Among them, Bartelink H et al reported that BCS has the equivalence with mastectomy [47] .…”